Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations

Executive Summary

FDA and industry have finally struck a tentative deal that, with Congressional approval, aims to raise nearly a billion dollars over five years. It also holds FDA to higher quality metrics while starting a pilot project to use real-world evidence in tracking devices on the market.


Related Content

NEST Executive Director: A One Woman Army
User-Fee Facts: 10 Key Medtech Details From US FDA Agreements
Trump Budget: FDA-Regulated Firms Should Pay 'Their Share' In User Fees
Device User-Fee Agreement Gets A Senate Hearing
MDUFA IV Fees Unveiled: Changes For 510(k)s, Small Business, De Novos
Public Invited To Vet Draft User-Fee Agreement At Nov. 2 Meeting
Next Steps For NEST: Planning Board Lays Out Launch Strategy For Evaluation System
FDA Moves Real-World Evidence Paradigm Forward With Draft Guidance
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed
Too Soon To Say If US FDA Device Reforms Are Working, Says Independent Report





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts